AA
TGTX icon

Ancora Advisors’s TG Therapeutics TGTX Stock Holding History

Ancora Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5K Sell
300
-1
-0.3% -$41 ﹤0.01% 1360
2026
Q1 		$10K Hold
301
– – ﹤0.01% 1772
2025
Q4 		$8.97K Hold
301
– – ﹤0.01% 1821
2025
Q3 		$10.9K Buy
+301
New +$9.91K ﹤0.01% 1373

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Ancora Advisors's TGTX Position: Q2 2026 in Review

Ancora Advisors reduced its TG Therapeutics (TGTX) stake by 0.33% in Q2 2026, selling an estimated $41 and leaving 300 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1360.

Ancora Advisors first reported a position in TGTX in Q3 2025 and has held it in 4 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Ancora Advisors held 300 shares of TG Therapeutics worth $16.5K as of Q2 2026.
  • Ancora Advisors sold 1 TG Therapeutics share in Q2 2026, an estimated $41.
  • TG Therapeutics made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #1360 holding.
  • Ancora Advisors first reported a position in TG Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.